1. Introduction {#s0005}
===============

Leigh syndrome (LS) (OMIM [256000](256000){#ir0010}) is an early onset, devastating neurodegenerative disease of the central nervous system (CNS) characterized by symmetrical necrotic lesions in the brainstem, basal ganglia and thalamus [@bb0005], [@bb0010]. The symptoms of LS include psychomotor retardation, respiratory difficulties, nystagmus, hypotonia, seizures, myoclonus, ataxia, dystonia, ptosis, ophthalmoplegia and high lactate levels in the blood and cerebrospinal fluid. Mutations in both mitochondrial DNA (mDNA) and nuclear DNA cause LS [@bb0015].

LS arises from a deficiency in the enzymes relating to energy production in the mitochondria, such as the respiratory chain complexes I--V, and the pyruvate dehydrogenase complex. Among the enzymes, isolated complex I deficiency is the most frequent oxidative phosphorylation (OXPHOS) defect in children with LS [@bb0020], [@bb0025], followed by a deficiency of complex IV (cytochrome C oxidase) and complex V (ATP synthase). Complex I is composed of seven mDNA encoded NADH dehydrogenase (ND) subunits (ND1--6, ND4L) and at least 38 nuclear DNA subunits [@bb0020]. An isolated generalized defect of complex IV is the second most common biochemical abnormalities found in patients with Leigh syndrome [@bb0030], [@bb0035]. *SURF1* mutations, which encode the putative assembly protein of complex IV, have been repeatedly reported [@bb0030].

Since a large number of genes are reportedly related to LS, molecular diagnosis appears challenging. However, emerging drugs for LS demand prompt diagnostic confirmation of LS. Although exome sequencing is a powerful method of suspected mitochondrial disorders, it is time and cost consuming, and impractical to be applied to all patients with LS. Based on the reported mutation information, we designed a small set of 21 primers that cover the gene in which LS mutations have been frequently reported [@bb0015]. In this study, we have examined the efficacy of our Sanger sequencing method as a genetic screening for LS in 18 unrelated LS cases from one children\'s hospital. We identified 7 patients with point mutations in mDNA including 2 cases in the *ATP6* gene and five in the *ND* genes. We also elucidated 4 mutations in the nuclear encoded gene, including 3 patients with a mutation in *SURF1* and 1 patient with a mutation in *PDHA1* (pyruvate dehydrogenase E1α-subunit). Our data suggest that Sanger screening using limited sets of primers is useful as first line screening for LS.

2. Methods {#s0010}
==========

We identified 18 patients from 16 families that met the criteria of LS at our institution (2005--2012). Diagnoses of LS were defined as presenting progressive neurologic disease with signs and symptoms of brain stem and/or basal ganglia abnormalities revealed on MR images. The clinical courses are summarized in [Table 1](#t0005){ref-type="table"} and Supplementary text. We have designed 7 sets of primers encoding mitochondrial derived subunits for complex I (*ND1-6*, *ND4L*) [@bb0015]. Primers were also designed on frequently reported gene *SURF 1* from complex IV [@bb0035] and *ATP synthase* from complex V [@bb0040]. If the blood lactate/pyruvate ratio is less than 10, we first sequenced the *PDHA1* gene ([Suppl. Fig. 1](#ec0020){ref-type="supplementary-material"}) [@bb0040]. Methods of genetic analysis, enzyme assays and determination of heteroplasmic rate and associated references are available in the online version of the paper (Suppl. text).

3. Results ([Table 1](#t0005){ref-type="table"}, [Suppl. Fig. 2](#ec0025){ref-type="supplementary-material"}) {#s0020}
=============================================================================================================

Of 18 LS patients, we identified gene mutations in 11 patients from 11 families ([Table 1](#t0005){ref-type="table"}, [Suppl. Fig. 2](#ec0025){ref-type="supplementary-material"}). mDNA mutations were identified in 7 patients. An *ND1* mutation of complex I (m3697G \> A, p.Gly131Ser) was identified in 2 individuals with homoplasmy. Mutations in *ND3* (m10158T \> C, p.Ser34Pro; mutant rate 90% in white blood cell), *ND5* (m13513G \> A, p.Asp393Asn; mutant rate 50% in white blood cell) and *ND6* (m14459G \> A, p.Ala71Val, homoplasmic state) were identified in a single patient, respectively. One severe patient died at 1 year, and carried a mutation in *ATP6* (m8993T \> G, p.Leu156Arg) of complex V of OXPHOS as a homoplasmic state. Instead of T \> G, T \> C mutation of the same nucleotide, m8993T \> C p.Leu156Pro, was observed with homoplasmy in a milder case.

Four patients were identified with mutations in nuclear DNA. *SURF1* mutations were identified in 3 cases, including 2 cases that were compound heterozygous (c.49 + 1G \> T/c.752_753delAG) and (c.574C \> T, p.Arg192Trp and c.743C \> A, p.Ala248Asp) and 1 case that was homozygous (c.743C \> A, p.Ala248Asp). One male patient was identified with a hemizygous mutation (c.121T \> C, p.Cys41 Arg) in *PDHA1*. Overall, we identified mutations in 61% of LS patients (11/18 individuals) in this cohort.

4. Discussion {#s0015}
=============

Molecular elucidation of LS at the DNA level is challenging. LS has been associated with a variety of genes in either mitochondrial or nuclear encoded DNA [@bb0015]. Surprisingly, we could reveal mutations in 61% of LS patients (11/18 individuals).

We disclosed 7 patients with mDNA mutations. From mitochondrial *ND1*, we identified an m3697G \> A mutation in 2 unrelated patients, which has been reported previously in association with mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes (MELAS) [@bb0045] and Leber\'s hereditary optic neuropathy (LHON) [@bb0050]. To our knowledge, this is the first report of the m3697G \> A/*ND1* gene mutation causing Leigh syndrome. The heteroplasmy rate is reportedly 80% in patients with MELAS (skeletal muscle) and was 56% with LOHN [@bb0045], [@bb0050]. A high mutation load (100%), found in the blood of Patients 1 and 2 may be associated to severe phenotype in our patients [@bb0055]. Low level of m3697G \> A mutation (\~ 40%) was found in the blood from an asymptomatic mother of Patient 1 (Suppl. Figs. 3 and 4).

For ND3, we found a mutation of m10158T \> C with 90% of heteroplasmic rate in one patient showing an early onset and very rapid progress. Severe clinical course and high mutant loads are consistent with reported cases with rapid progression and lethal consequences at early childhood [@bb0060]. A mutation of m10158T \> C was not detected in the mother of Patient 3 in several tissues examined.

We found one patient with ND5 mutation, m13513G \> A which has been described as causing MELAS, LS or overlapping features of the two syndromes [@bb0065], [@bb0070], [@bb0075]. We also found one LS patient with m14459G \> A/*ND6* mutation that was reported in patients with LHON, dystonia [@bb0080] and LS [@bb0085]. So far, the phenotype of these two patients is LS without MELAS, LHON.

We found two patients with *ATPase6* mDNA mutations, m8993T \> G and T \> C, that are frequently reported in the literature [@bb0040]. A patient with a T \> G mutation usually exhibits earlier onset and more rapid progression compared to T \> C mutation at m8993 that was compatible with our patients ([Table 1](#t0005){ref-type="table"}).

We found 4 patients carrying nuclear encoded gene mutations. SURF1 deficiency is the most frequent cause of LS with complex IV (cytochrome C oxidase) deficiency [@bb0035]. We identified 3 patients with the *SURF1* mutations [@bb0090]. Pyruvate dehydrogenase deficiency (PDH) is a common cause of primary congenital lactic acidosis. The biochemical features of PDH deficiency is elevated blood lactate and pyruvate levels with a normal lactate/pyruvate ratio [@bb0095]. According to the genetic screening flowchart for Leigh syndrome ([Suppl. Fig. 1](#ec0020){ref-type="supplementary-material"}), we confirmed 1 patient with a hemizygous mutation in the *PDHA1* gene with 7 sets of primers.

Recently, new drugs such as EPI-743 have been shown to improve neurological and neuromuscular symptoms in LS [@bb0100], [@bb0105]. Rapid genetic confirmation of mitochondrial disease may help initiate such treatment early. Next gene sequencing is revealing a wide range of dual mutations both mitochondrial and nuclear gene from patients with mitochondrial disorders [@bb0110], [@bb0115], [@bb0120]. However, it is costly and time consuming. Aiming to elucidate genetic basis of LS patients, we screened with our limited set of primers. Surprisingly, it allowed us confirmation for more than half of the patients. Therefore, this method appears to be efficient as a primary genetic screening. Our data also implicates that LS consisted of few "common" causative genes and a large number of "rare" genes. We are now undertaking whole mDNA and exome sequencing for negative cases of this method [@bb0110], [@bb0115], [@bb0120]. These data, together with increasing data of mutations, would help us improve our screening method.

The following are the Supplementary data related to this articleSupplemental Table 1Primers for PCR and PCR conditions.Supplemental Table 2Biochemical studies of electron transport chain enzyme complexes.Supplemental TextClinical courses of patients.Supplemental Fig. 1Primary genetic screening flowchart for Leigh syndrome.Supplemental Fig. 2Magnetic resonance imaging (MRI) of the patients included in this study. (Panel A, Patient 1, B; Patient 2, C; Patient 4, D; Patient 5, E; Patient 6, F and G; Patient 7, H; Patient 10, I; Patient 11). T2-weighted images show various degrees of striatal high intensity lesion in the putamina and caudate nuclei (panels A--D, F). A diffusion weighted image reveals high intensity in the part of bilateral basal ganglia (panel E). Panels G and I show high intensity areas in the dorsal pons and cerebellar white matter. Panel H shows small high intensity areas in the dorsal pons and mild cerebellar atrophy.Supplemental Fig. 3. Molecular genetic analysis of the m3697G \> A (G131S) mutation. Sequence electropherograms illustrating the m3697G \> A substitution disclosed in the control sample (A), in blood from Patient 1 (B) and his mother (C), sequence variants in the blood (D), saliva (E), hair (F) and nail (G) from Patient 2.Supplemental Fig. 4. LC hybridization probes in quantification and genotyping. Melting curve analysis for standard using wild-type and mutant plasmids (A). Mutant load in blood from Patient 1 and his mother and some tissues (blood, saliva, hair and nail) from Patient 2 (B).
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Genetically determined Leigh syndrome in our institution (2005--2012).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient                            1                       2                      3                      4                       5                      6                       7                      8                   9                    10                      11
  ---------------------------------- ----------------------- ---------------------- ---------------------- ----------------------- ---------------------- ----------------------- ---------------------- ------------------- -------------------- ----------------------- ------------------
  Age, gender                        7 y, M                  10 y, F                9 m, F                 7 y, M                  11 y, M                1 y✝, M                 2 y, M                 4 y, F              9 y, M               25 y✝, M                17 y, M

  Type of gene                       Mito                    Mito                   Mito                   Mito                    Mito                   Mito                    Mito                   Nuclear             Nuclear              Nuclear                 Nuclear

  Gene                               *ND1*                   *ND1*                  *ND3*                  *ND5*                   *ND6*                  *ATPase6*               *ATPase6*              *SURF1*             *SURF1*              *SURF1*                 *PDHA1*

  Complex                            I                       I                      I                      I                       I                      V                       V                      IV                  IV                   IV                      

  Mutations                          m3697G\>A (p.G131S)\    m3697G\>A (p.G131S)\   m10158T\>C (p.S34P)\   m13513G\>A (p.D393N)\   m14459G\>A (p.A71V)\   m8993T\>G (p.L156R)\    m8993T\>C (p.L156P)\   c.49+1G\>T          c.743 C\>A p.A248D   c.574C\>T p.R192 W      c.121T\>C p.C41R
                                     Homo\                   Homo\                  Hetero (90%)\          Hetero (50%)\           Homo\                  Homo\                   Homo\                                                                                   
                                     (b)                     (b,s,h,n)              (b)                    (b)                     (b)                    (b)                     (b)                                                                                     

  c.752--753delAG                    c.743C\>A p.A248D       c.743C\>A p.A248D                                                                                                                                                                                            

  Consanguinity                      N                       N                      N                      N                       N                      N                       N                      N                   Y                    N                       N

  Inheritance                        Maternal\* hetero:40%   N.A.                   De novo                N.A.                    N.A.                   N.A.                    N.A.                   Maternal/paternal   Maternal/paternal    N.A.                    N.A.

  Age at onset                       3 y 9 m                 3 y 0 m                0 y 5 m                1 y 6 m                 2 y 0 m                6 m                     1 y 0 m                1 y 7 m             1 y 9 m              2 y                     1 y 0 m

  Initial Symptoms                   Hypertonia\             Ataxic gait\           Hypotonia\             Dev. delay              Fever → lethargy       Dev. delay/seizure\     Fever → lethargy       Ataxic gait         Ataxic gait          Dev. delay\             Dev. delay
                                     Walk regre              Walk regre\            Strabismus                                                            Hypotonia/nystagmus                                                                     Ataxia                  
                                                             Tremor                                                                                                                                                                                                       

  Status                             Walk\                   Wheelchair\            Tracheo\               Walk                    Wheelchair\            (Respiratory failure)   No sitting             Tracheo\            Tracheo\             (Respiratory failure)   Walk\
                                     Normal class            Special class          Mech. venti                                    Normal class                                                          Mech. venti         Mech. venti                                  Special school

  RC enzymes ↓                       I, IV (m)               I, III, IV (m)         I (f)                  Normal (m/f)            I, III (m)             I, IV (m)               N.A.                   N.A.                IV (f)               IV (m)                  N.A.

  Morphological findings in muscle   No RRF                  No RRF                 N.A.                   No RRF                  RRF                    N.A.                    N.A.                   N.A.                N.A.                 RRF                     N.A.

                                                                                                                                                                                                                                                                          

  *MRI*                                                                                                                                                                                                                                                                   

  Basal ganglia hyperintensities     Y                       Y                      Y                      Y                       Y                      Y                       Y                      Y                   Y                    Y                       Y

  Brainstem hyperintensities         N                       Y                      Y                      N                       N                      N                       Y                      Y                   Y                    Y                       N

  Cerebellar atrophy                 N                       N                      N                      Y                       N                      N                       N                      N                   N                    Y                       Y

                                                                                                                                                                                                                                                                          

  *Symptoms*                                                                                                                                                                                                                                                              

  Dysmorphisms                       N                       N                      N                      N                       N                      N                       N                      Y                   Y                    N                       N

  Developmental delay                N                       N                      Y                      Y                       N                      N                       Y                      Y                   Y                    Y                       N

  Regression                         Y                       Y                      Y                      N                       N                      Y                       Y                      Y                   Y                    Y                       N

  Feeding problems                   N                       N                      Y                      N                       N                      Y                       N                      N                   N                    N                       N

  Ptosis                             N                       N                      N                      N                       N                      N                       N                      Y                   N                    N                       N

  Ophthalmople                       N                       N                      Y                      N                       N                      N                       N                      Y                   N                    Y                       N

  Pyramidal symptoms                 Y                       Y                      Y                      Y                       Y                      N                       N                      Y                   Y                    N                       Y

  Extrapyramidal symptoms            Y                       Y                      Y                      Y                       N                      Y                       N                      Y                   Y                    N                       Y

  Dystonia                           Y                       Y                      Y                      N                       N                      N                       N                      Y                   Y                    N                       Y

  Hypotonia                          N                       N                      Y                      Y                       N                      Y                       Y                      Y                   Y                    N                       Y

  Ataxia                             Y                       Y                      Y                      Y                       N                      N                       N                      Y                   Y                    Y                       Y

  Neuropathy                         N                       N                      N                      N                       N                      N                       N                      Y                   Y                    Y                       Y

  Others                                                                                                   WPW syndrome                                   West syndrome                                                                                                   Nystagmus
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

y: year, m: month, M: male, F: female, mito: mitochondria, Complex: complex in oxidative phosphorylation, b: blood, s: saliva, h: hair, n: nail, RC: respiratory chain, m: muscle, f: fibroblast, RRF: ragged red fibers, N.A.: not analyzed/not determined, N: no, negative, Y: yes, positive, regre: regression, Dev. delay: Developmental delay, Mech.venti: Mechanically ventilated, Ophthalmople: Ophthalmoplegia, \*: asymptomatic.
